Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 May;36(3):198–204. doi: 10.1007/BF01741092

HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients

Richard A J Janssen 1,✉, Jan Buter 2, Elske Straatsma 1, Agnes A Heijn 1, Dirk Th Sleijfer 2, Elisabeth G E de Vries 2, Nanno H Mulder 2, T Hauw The 1, Lou de Leij 1
PMCID: PMC11038639  PMID: 8439981

Abstract

The effect of subcutaneous recombinant interleukin-2 (rIL-2) therapy on the “activation status” of peripheral blood lymphocytes (PBL) of 17 renal cell carcinoma patients was investigated in a longitudinal study. The expression of the activation markers HLA-Dr and CD25 on cytotoxic T cells, helper T cells, and natural killer (NK) cells, was analysed using two-colour flow cytometry of whole-blood samples. In addition, the ability of isolated PBL to proliferate in vitro in response to various stimuli was investigated. The absolute amounts of NK cells and HLA-DR-expressing NK cells increased continuously during the whole course of therapy. The absolute amounts of T cells and HLA-Dr-expressing T cells, however, showed an early increase only during the first 1 or 2 weeks of therapy, after which the absolute amounts of HLA-Dr-expressing T cells decreased. In particular, the absolute amount of HLA-Dr-expressing CD8bright+ T cells was significantly lowered in the second half of therapy. PBL collected on day 7 of therapy (post-cycle-1 PBL) showed, as compared to those collected prior to therapy (pretherapy PBL), a decreased proliferative response in vitro after stimulation with phytohaemagglutinin, concanavalin A, soluble CD3 mAb (WT32) or rIL-2. This decreased in vitro response of post-cycle-1 PBL was also reflected in a decrease in the percentage of CD8bright+ T cells expressing HLA-Dr in cultures with rIL-2 or CD3 mAb, in contrast to cultures of pretherapy PBL, which showed an increase of this percentage. We conclude that T cells are the predominantly stimulated subpopulation during the first 2 weeks of subcutaneous rIL-2 therapy. The significant decrease in the absolute amounts of HLA-Dr-expressing T cells in the peripheral blood during the second half of therapy may partly be explained by a decreased responsiveness to rIL-2, but a selective redistribution of HLA-Dr-expressing cells may also be involved.

Key words: Renal cell carcinoma, rIL-2, Lymphocyte phenotype, HLA-Dr

References

  • 1.Cantrell DA, Smith KA. The interleukin-2 T-cell system: a new cell growth model. Science. 1984;224:1312. doi: 10.1126/science.6427923. [DOI] [PubMed] [Google Scholar]
  • 2.Ellis TM, Creekmore SP, McMannis JD, Braun DP, Harris JA, Fisher RI. Appearance and phenotypic characterization of circulating leu 19+ cells in cancer patients receiving recombinant interleukin 2. Cancer Res. 1988;48:6597. [PubMed] [Google Scholar]
  • 3.Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, Bijmann JT, Franks CR, Mercatello A, Phillip T. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma. J Biol Response Mod. 1990;9:167. [PubMed] [Google Scholar]
  • 4.Hank JA, Sosman JA, Kohler PC, Bechhofer R, Storer B, Sondel PM. Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2. J Biol Response Mod. 1990;9:5. [PubMed] [Google Scholar]
  • 5.Hänninen EL, Körfer A, Hadam M, Schneekloth C, Dallmann I, Menzel T, Kirchner H, Poliwoda H, Atzpodien J. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes. Cancer Res. 1991;50:6312. [PubMed] [Google Scholar]
  • 6.Ko HS, Fu SM, Winchester RJ, Yu DTY, Kunkel HG. Ia determinants on stimulated human T lymphocytes. Occurence on mitogen- and antigen-activated T cells. J Exp Med. 1979;150:246. doi: 10.1084/jem.150.2.246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Rosenberg SA, Lotze MT, Muul IM, Chang AE, Avis FP, Leitman S, Linehan M, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  • 8.Sleijfer DTh, Janssen RAJ, Willemse PHB, Martens A, de Leij L, de Vries EGE, Mulder NH. Low-dose regimen of interleukin-2 for metastatic renal carcinoma. Lancet. 1990;335:1522. doi: 10.1016/0140-6736(90)93057-v. [DOI] [PubMed] [Google Scholar]
  • 9.Sleijfer DTh, Janssen RAJ, Buter J, de Vries EGE, Willemse PHB, Mulder NH. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol. 1992;10:1119. doi: 10.1200/JCO.1992.10.7.1119. [DOI] [PubMed] [Google Scholar]
  • 10.Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, Bechhofer R, Storer B. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res. 1988;48:2561. [PubMed] [Google Scholar]
  • 11.Talmadge JE, Wiltrout RH, Counts DF, Herberman RB, McDonald T, Ortaldo JR. Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes. Cell Immunol. 1986;102:261. doi: 10.1016/0008-8749(86)90420-x. [DOI] [PubMed] [Google Scholar]
  • 12.Tax WJM, Willems HW, Reekers PPM, Capel PJ, Koene RAP. Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells. Nature. 1983;304:445. doi: 10.1038/304445a0. [DOI] [PubMed] [Google Scholar]
  • 13.Thi Bich-Thuy L, Lane HC, Fauci AS. Recombinant interleukin-2 induced polyclonal proliferation of in vitro unstimulated human peripheral blood lymphocytes. Cell Immunol. 1986;98:396. doi: 10.1016/0008-8749(86)90299-6. [DOI] [PubMed] [Google Scholar]
  • 14.Urba WJ, Steis RG, Longo DL, Kopp WC, Maluish AE, Marcon L, Nelson DL, Stevenson HC, Clark JW. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res. 1990;50:185. [PubMed] [Google Scholar]
  • 15.Weil-Hillman G, Hank JA, Rosenthal NS, Sondel PM. Transient decrease in Il-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients. J Biol Response Mod. 1988;7:424. [PubMed] [Google Scholar]
  • 16.Weil-Hillman G, Fisch P, Prieve AF, Sosman JA, Hank JA, Sondel PM. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu 19 antigens but negative expression of CD16 antigens. Cancer Res. 1989;49:3680. [PubMed] [Google Scholar]
  • 17.Weil-Hillman G, Schell K, Segal DM, Hank JA, Sosman JA, Sondel PM. Activation of human T cells obtained pre- and post interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: inplications for combined in vivo treatment. J Immunother. 1991;10:276. doi: 10.1097/00002371-199108000-00005. [DOI] [PubMed] [Google Scholar]
  • 18.West WH, Tauer KW, Yanelli JR, Marshall GD, Orr DW, Thjurman GB, Oldhan RK. Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987;316:898. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES